Immunovant logo

ImmunovantNASDAQ: IMVT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 June 2019

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$4.30 B
-33%vs. 3y high
88%vs. sector
-vs. 3y high
-vs. sector
-68%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 20:20:00 GMT
$29.39+$0.17(+0.58%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

IMVT Latest News

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
zacks.com09 September 2024 Sentiment: POSITIVE

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.

Immunovant Provides Update on Graves' Disease Development Program
globenewswire.com09 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024.

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
benzinga.com09 September 2024 Sentiment: NEUTRAL

Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
globenewswire.com29 May 2024 Sentiment: POSITIVE

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024.

Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
investors.com29 May 2024 Sentiment: NEGATIVE

Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.

Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
Zacks Investment Research13 May 2024 Sentiment: POSITIVE

On Wall Street, analysts have set an average price target for Immunovant (IMVT) that suggests a potential increase of 68.6%. Although the reliability of this metric is uncertain, the positive trend in earnings estimates could lead to a rise in the stock price.

What Makes Immunovant (IMVT) a New Buy Stock
Zacks Investment Research17 April 2024 Sentiment: POSITIVE

There is increasing optimism about Immunovant's earnings prospects, leading to its upgrade to a Zacks Rank #2 (Buy) and potentially causing the stock to rise.

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Seeking Alpha04 April 2024 Sentiment: POSITIVE

Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advancing toward registrational trials. Financial health appears strong with a 40-month cash runway, but increased R&D could affect this.

Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
Zacks Investment Research13 March 2024 Sentiment: NEGATIVE

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
Zacks Investment Research08 March 2024 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Immunovant, Inc. (IMVT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

  • 1(current)

What type of business is Immunovant?

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

What sector is Immunovant in?

Immunovant is in the Healthcare sector

What industry is Immunovant in?

Immunovant is in the Biotechnology industry

What country is Immunovant from?

Immunovant is headquartered in United States

When did Immunovant go public?

Immunovant initial public offering (IPO) was on 21 June 2019

What is Immunovant website?

https://immunovant.com

Is Immunovant in the S&P 500?

No, Immunovant is not included in the S&P 500 index

Is Immunovant in the NASDAQ 100?

No, Immunovant is not included in the NASDAQ 100 index

Is Immunovant in the Dow Jones?

No, Immunovant is not included in the Dow Jones index

When was Immunovant the previous earnings report?

No data

When does Immunovant earnings report?

The next expected earnings date for Immunovant is 08 November 2024